ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $225,437 | -59.2% | 4,887 | -63.4% | 0.06% | -70.7% |
| Q3 2022 | $553,000 | +41.1% | 13,355 | +147.7% | 0.22% | -1.4% |
| Q1 2022 | $392,000 | -23.3% | 5,392 | +0.5% | 0.22% | -53.1% |
| Q2 2021 | $511,000 | +150.5% | 5,364 | +66.9% | 0.46% | +244.4% |
| Q2 2019 | $204,000 | -61.6% | 3,214 | -71.9% | 0.14% | -12.9% |
| Q4 2017 | $531,000 | +149.3% | 11,453 | +186.3% | 0.16% | +158.3% |
| Q3 2017 | $213,000 | -27.1% | 4,000 | +53.8% | 0.06% | -73.5% |
| Q4 2015 | $292,000 | – | 2,600 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |